HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: NARB allows MidNite PM “faster” claim, Oral-B survives ad challenge, For Goodness Shakes’ online ad offensive

This article was originally published in The Tan Sheet

Executive Summary

NARB allows “faster” sleep claim for MidNite PM; P&G survives ad challenge; Cardium sells To Go; OxyElite Pro recall expanded; FDA warns of tainted supplements; For Goodness Shakes’ Internet video offensive; and CHPA nominates Pediatric Advisory Committee members.

You may also be interested in...

Wink's Ad Claims For Children's Melatonin Fail In Review From J&J Challenge

NAD advises Wink Naturals to discontinue online and social media claims that its melatonin-containing supplements for children are “appropriately dosed for children” and their delivery method is superior to competing products.

Japan Helps Bayer’s Eylea Sales To Sparkle

Eye disease drugs have struggled to grow during the pandemic but Bayer's Regeneron-partnered blockbuster is going from strength to strength, helped by growth in Japan.

EU Launches Faster Process For Approving Variant Vaccines

Amid the growing threat posed by variants of the coronavirus, the European Commission has published new rules allowing modified vaccines to be approved more quickly. The UK has identified one version of the B.1.167 virus variant as the most transmissible, although the jury is still out on its ability to evade vaccine protection.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts